News & Media

2025-07-04

World-Class Experts Join Immuthera’s Scientific Advisory Board

2025-06-20

PolTREG at  BIO International Convention 2025

2025-06-13

PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy

2025-05-14

PolTREG Q1 2025 financial results webinar

2025-04-23

PolTREG accelerates the development of next-generation antigen-specific Tregtherapy for Type 1 Diabetes

2025-04-18

PolTREG Expands U.S. Market Presence with New Kubera N.A. LLC Collaboration

2025-03-27

PolTREG partners with Noble Capital Markets Inc. to prepare for potential fundraising in the U.S.

2025-03-25

Webinar: PolTREG’s Strategic Collaboration with Antion Biosciences and Growth Prospects for 2025

2025-03-21

PolTREG Forms Strategic Partnership with Antion Biosciences to Develop Next-Generation Allogeneic CAR-Treg Therapies

2025-02-25

PolTREG partners with Kinexum to advance TREGS therapy registration in the U.S. 

2025-01-20

PolTREG secures PLN 51.4M grant recommendation from Polish Agency for Enterprise Development for groundbreaking multiple sclerosis therapy

2025-01-09

PolTREG obtains Japanese patent for intrathecal PTG-007 therapy in multiple sclerosis